3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
3
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Melanoma
4
Neoplasm Metastasis
3
Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Neoplasms
1
HTLV-I Infections
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Imatinib Mesylate
23
Cyclophosphamide
18
fludarabine
17
fludarabine phosphate
13
Busulfan
12
Whole-Body Irradiation
11
nilotinib
10
Dasatinib
9
thymoglobulin
8
ponatinib
8
Mycophenolic Acid
8
Cytarabine
7
Antilymphocyte Serum
7
peginterferon alfa-2b
6
Tacrolimus
6
Cyclosporine
6
Clofarabine
6
Thiotepa
5
Stem Cell Transplantation
4
Sirolimus
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Alemtuzumab
4
sargramostim
3
Interferon-alpha
3
Homoharringtonine
3
Cord Blood Stem Cell Transplantation
3
Bortezomib
3
zileuton
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Interferon alpha-2
×
Clear all
NCT03547154
2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3
Terminated
344 enrolled
11 charts